CD19-targeted mRNA therapy delivered by lipid nanoparticles for B-cell blood cancers
Official title: Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
Run by Xinqiao Hospital of Chongqing · NCT07349849 · Data updated 2026-11-12
It will try a lipid-nanoparticle mRNA therapy that generates CD19-targeted CAR-T activity inside the body for adults (18–70) with relapsed or refractory CD19-positive B-cell leukemia or lymphoma who have no standard treatment options.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 47 (estimated) |
| Sponsor | Xinqiao Hospital of Chongqing Academic / other |
| Drugs / interventions | chimeric antigen receptor |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Status | Recruiting |
| Started | December 20, 2025 |
| Main results expected | January 1, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | January 20, 2026 |
| Trial ID | NCT07349849 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–70 with confirmed CD19-positive B-cell lymphoma or lymphocytic leukemia, expected survival over 12 weeks, ECOG 0–1, measurable disease where required, and no guideline-recommended standard treatment options are the intended candidates.
✕Probably not a fit
Patients who previously received CAR-T or other transgenic T-cell therapies, have uncontrolled HIV/HBV/HCV infection, CNS lymphoma or brain metastases, other uncontrolled malignancies, or poor performance status are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early Phase 1 interventional trial will administer an in vivo CAR-T drug formulated as lipid nanoparticle (LNP) mRNA encoding a CD19-targeting construct to adult patients with CD19-positive B-cell malignancies. The LNPs protect the mRNA and promote intracellular delivery so the patient's own T cells can translate the CAR construct without ex vivo cell manufacturing. As an early-phase trial the primary focus is on safety, tolerability, and initial dosing, with close monitoring for immune-related toxicities and any anti-tumor activity. The single-center study is conducted at Xinqiao Hospital in Chongqing and enrolls adults with adequate organ function and ECOG performance status 0–1 who meet the listed inclusion and exclusion criteria.
Why it matters
Potential benefit: If successful, this could provide a less complex, non-viral way to generate CD19-directed CAR-T activity and offer a treatment option for patients without standard therapies.
How similar studies have gone: mRNA LNP technology has proven successful for vaccines and ex vivo CD19 CAR-T therapies are effective, but in vivo LNP-mediated CAR-T for CD19 is largely novel and unproven in humans.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Age range of 18-70 years old, gender not limited; * 2\. Expected survival time exceeds 12 weeks; * 3\. B-cell lymphoma or lymphocytic leukemia diagnosed with CD19+, with no standard treatment options recommended according to guidelines * 4\. There are assessable lesions (applicable only to lymphoma patients); * 5\. The physical fitness status score of the Eastern Cancer Collaboration Group (ECOG) is 0 or 1; * May involve other inclusion criteria Exclusion Criteria: * 1\. Accompanied by other uncontrolled malignant tumors; * 2\. Previously received chimeric antigen receptor therapy or other transgenic T cell therapy; * 3\. Known history of HIV or hepatitis B (HBsAg positive and HBV DNA reaching the detection limit) or hepatitis C virus (anti HCV positive) infection; * 4\. Participants with a history of CNS lymphoma, malignant cells in cerebrospinal fluid, or brain metastases; * 5\. The researcher believes that there are any other factors that are not suitable for the study participants to enter this trial. May involve other exclusion criteria
Where it's running
-
Department of Hematology, Xinqiao Hospital
Chongqing, Chongqing Municipality, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Emavusertib plus zanubrutinib for CLL and other B‑cell cancers
This test will see if adding emavusertib to the BTK inhibitor zanubrutinib can reduce measurable residual disease in adults with chronic lymphocytic leukemia or other B‑cell malignancies.
-
Anti-CD22 CAR‑T cell therapy for CD22‑positive B‑cell cancers
This trial will try a one-time CAR‑T cell therapy that targets CD22 in children and adults whose relapsed or refractory B‑cell cancers still express CD22 after prior treatments, including CD19‑directed therapy.
-
JY231 injection for relapsed or refractory CD19-positive B-cell malignancies
This trial will test whether a single intravenous injection of JY231, an in vivo CAR-T therapy, can help adults with relapsed or refractory CD19-positive B-cell malignancies.
-
Evaluating SYS6005 for advanced malignant tumors
This study is testing a new treatment called SYS6005 to see if it is safe and effective for people with advanced malignant tumors.
-
Evaluating a new T cell-engaging antibody for B-cell cancers
This study is testing a new antibody treatment for people with tough-to-treat B-cell cancers to see if it is safe and effective after they have already tried other therapies.
-
Treatment with anti-CD19-CAR-T cells for patients with relapsed B-cell tumors
This study is testing a new treatment using anti-CD19-CAR-T cells to see if it can help patients with relapsed B-cell tumors feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.